Company Overview and News

0
Perseus Mining Ltd (PMNXF) CEO Jeff Quartermaine on Q4 2018 Results - Earnings Call Transcript

2018-07-13 seekingalpha
Thank you for standing by and welcome to Perseus Mining's June 2018 Quarterly Conference Call. All participants are in a listen only mode. There will be a presentation followed by a question-and-answer session. [Operator Instructions]
PMNXF PRU PRU

0
Perseus Mining reveals increasing production and decreasing costs in Quarterly Report

2018-07-12 proactiveinvestors.com.au
Perseus Mining Limited (ASX:PRU) (TSX:PRU) chief executive Jeff Quartermaine tells Proactive Investors all the highlights contained in the gold producer's just-released Quarterly Report.
PMNXF PRU PRU

0
Perseus Mining Limited: Activity Report for June 2018 Quarter

2018-07-12 globenewswire
PERTH, Western Australia, July 12, 2018 (GLOBE NEWSWIRE) -- Perseus Mining Limited (“Perseus” or the “Company”) (TSX:PRU) (ASX:PRU) reports on its activities for the three month period ended June 30, 2018 (the “Quarter”). An executive summary is provided below. However, full details of activities in the June Quarter, including reconciled production and all-in site cash costs, are included in the Company’s June 2018 Quarterly Activity Report released to the market on July, 13, 2018.
PMNXF MALRY PRU MALRF PRU MIN

0
Mako Gold intersects significant gold mineralisation at Napié project

2018-07-09 proactiveinvestors.com.au
Mako Gold Ltd (ASX:MKG) has intersected significant widths and grades of gold mineralisation from all three of its southern high priority targets at the Napié project in Côte d’Ivoire.
PMNXF PRU PRU

0
Perseus Mining Limited: June 2018 Quarterly Activity Report Conference Call

2018-07-09 globenewswire
PERTH, Australia, July 09, 2018 (GLOBE NEWSWIRE) -- Perseus Mining Limited (ASX:PRU) (TSX:PRU) is hosting a conference call to discuss the June 2018 Quarterly Report, which is anticipated for release around 8.30am AEDT on Friday July 13, 2018.
PMNXF PRU PRU

2
Australian shares higher on financial rebound ahead of trade tariff deadline

2018-07-05 theage.com.au
Australian shares advanced for just the third time in ten sessions as modest gains by the finance sector beat out losses made in the material sector following an overnight base metal retreat.
NCMGF NCM RIO BLT RIO EVN BHPBF PRU RSG RTPPF NCMGY RMGGY BHP RIO PMNXF RMGGF RTNTF BBL BHP CAHPF PRU BHPLF

2
Australian shares higher on financial rebound ahead of trade tariff deadline

2018-07-05 smh.com.au
Australian shares advanced for just the third time in ten sessions as modest gains by the finance sector beat out losses made in the material sector following an overnight base metal retreat.
NCMGF NCM RIO BLT RIO EVN BHPBF PRU RSG RTPPF NCMGY RMGGY BHP RIO PMNXF RMGGF RTNTF BBL BHP CAHPF PRU BHPLF

0
Perseus Mining delivers record gold production

2018-07-04 proactiveinvestors.com.au
Perseus Mining Ltd (ASX:PRU) has produced a record 83,881 ounces of gold from its Edikan and Sissingue gold mines in West Africa.
PMNXF PRU PRU

0
Perseus delivers record gold production

2018-07-04 australianmining.com.au
Perseus Mining’s transformation into a multi-mine West African gold company has gone to plan so far in 2018.
PMNXF PRU PRU

0
Perseus Mining Delivers Record Gold Production in June 2018 Quarter

2018-07-04 globenewswire
PERTH, Australia, July 04, 2018 (GLOBE NEWSWIRE) -- Perseus Mining Limited (ASX:PRU)(TSX:PRU) is pleased to report that in the period to June 30, 2018, the group has produced a record quantity of gold from its two West African mines and in the process has emphatically demonstrated the success of its plan to transform from a single mine producer into a successful multi-mine, West African focussed explorer, developer and gold producer.
PMNXF PRU PRU

0
Mako Gold intersects wide, high-grade gold in maiden drilling program at Côte d’Ivoire

2018-06-22 proactiveinvestors.com.au
Mako Gold Ltd (ASX:MKG) has received assay results from its maiden reverse circulation (RC) drilling program at the Napié Project in Côte d’Ivoire.
PMNXF PRU PRU

9
Asante & Perseus Modify Betenase Option, Ghana

2018-06-05 globenewswire
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO U.S. NEWS AGENCIES
AULGF PMNXF AU ASGOF AGG PRU PRU

38
10 Best Risk/Reward Leveraged Gold Stocks

2018-06-01 seekingalpha
Below is a list of 10 quality gold producers. I have selected them as the best risk/reward leveraged gold stocks. All of these should outperform the price of gold if it rises. In fact, I expect all of these stocks to double in value if gold reaches $1,600. These are the stocks that you want to own if you are looking for high returns if gold prices start trending. Also, if you are looking for a way to hedge against a market crash, then these stocks offer a potential hedge.
NGDAF ARNGF NGD TGD MUX.RTWI HUMRF DGC EDVVF PMNXF GCM.WT.A PRU MUX AR HTXFF HUM EDV RPM NGD ALO MUX TPWRF WDO EDVMF RPMGD DRGDF RPMGF PRU TPRFF GCM TMM EVR WDOFF

0
Perseus Mining moving from one mine one country operator to multi mine and jurisdictional business

2018-05-09 proactiveinvestors.com.au
Perseus Mining Limited (ASX:PRU) (TSX:PRU) CEO Jeff Quartermaine tells Proactive Investors over the next four years the mining company hopes to increase production to around 500,000 ounces of gold per year with three operating mines in West Africa by 2020.
PMNXF PRU PRU

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...